- Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.
2026
- Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada
Canadian Medical Association Journal · 2026
- Comparative effectiveness of combination therapy with <scp>SGLT</scp> ‐2 inhibitors and <scp>GLP</scp> ‐1 <scp>RAs</scp> compared with <scp>SGLT</scp> ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
Diabetes Obesity and Metabolism · 2026
- Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis
Obesity Surgery · 2026
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis
Renal Failure · 2026
- Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives
Kidney Medicine · 2026
- Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial
Journal of Surgical Research · 2026
- Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV)
BMJ Open · 2026
- The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials
Therapeutic Advances in Musculoskeletal Disease · 2026
- Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis
CJC Open · 2026
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials
European journal of medical research · 2026
- GLP-1 receptor agonists, SGLT-2 inhibitors and their combination: effects on carotid atherosclerosis regression, oxidative stress and amyloid-β1-40 in diabetes
American Journal of Physiology-Heart and Circulatory Physiology · 2026
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Diabetes Research and Clinical Practice · 2026
- The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus
Current Diabetes Reviews · 2026
- Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels
Cardio-Oncology · 2026
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
Diabetes Therapy · 2026
- Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management
Endocrinology Diabetes & Metabolism · 2026
- A Nationwide Danish Comparative Effectiveness Study of <scp>GLP</scp> ‐1 <scp>RA</scp> , <scp>SGLT2i</scp> and <scp>DPP</scp> ‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes
Endocrinology Diabetes & Metabolism · 2026
- Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists
Cardiovascular Therapeutics · 2026
- Correction to “Clinical Profiles and In‐Hospital Outcomes of Pre‐Existing Versus Newly Diagnosed Atrial Fibrillation in Coronary Care Units: Insights From the <scp>MORCOR</scp> ‐ <scp>TURK</scp> National Registry”
Journal of Arrhythmia · 2025
- Efficacy and Safety of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
2025
- Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States
Journal of Managed Care & Specialty Pharmacy · 2025
- Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China.
2025
- The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
Reviews in Cardiovascular Medicine · 2025
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
New England Journal of Medicine · 2025
- GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
European Heart Journal · 2025
- Obesity burden among heart failure patients in an urban safety net hospital: Implications for GLP-1 agonist therapy
American Heart Journal Plus Cardiology Research and Practice · 2025
- GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases
Current Problems in Cardiology · 2025
- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials
BMC Cardiovascular Disorders · 2025
- Body-wide multi-omic counteraction of aging with GLP-1R agonism
Cell Metabolism · 2025
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD
American Journal of Kidney Diseases · 2025
- Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management
Clinical Pharmacology in Drug Development · 2025
- Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes
Diabetes Care · 2025
- Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
Biomolecules · 2025
- GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
International Journal of Molecular Sciences · 2025
- Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking
European Heart Journal · 2025
- Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
Diabetes Obesity and Metabolism · 2025
- Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials
Diabetes Obesity and Metabolism · 2025
- Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery
Global Spine Journal · 2025
- GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes
Journal of the American Geriatrics Society · 2025
- Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis
British Journal of Pharmacology · 2025
- Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study
Circulation Arrhythmia and Electrophysiology · 2025
- Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings
Journal of Orthopaedic Surgery and Research · 2025
- Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes
Cardiovascular Diabetology · 2025
- Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis
Frontiers in Cardiovascular Medicine · 2025
- Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis
Cardiovascular Diabetology · 2025
- Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to <scp>HbA1c</scp> lowering in type 2 diabetes: An updated meta‐regression analysis incorporating <scp>FLOW</scp> and <scp>SOUL</scp> trials
Diabetes Obesity and Metabolism · 2025
- Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups
Pharmacoepidemiology and Drug Safety · 2025
- Prevalence of <scp>SGLT2</scp> inhibitor and <scp>GLP1</scp> receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
Diabetes Obesity and Metabolism · 2025
- From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model
CPT Pharmacometrics & Systems Pharmacology · 2025